Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

May 26, 2022

Submitted by: Aristotle Protopapas

Source: The New England Journal of Medicine

Source URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2202170?query=TOC&cid=NEJM%20eToc%2C…

Keywords:

Author(s): the CheckMate 816 Investigators

No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question….

Add Comments Cancel reply

You must be logged in to post a comment.

AI-Powered Oral Board Training Is Available to CTSNet Users Now!

AI-Powered Oral Board Training Is Available to CTSNet Users Now!

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Add Comments Cancel reply

Related Content

The Beat With Joel Dunning Ep. 174: Surgical Treatment of Atrial Fibrillation

CT Findings Maintains the Predictive Performance of an Existing Radiograph-Based Donor Lung Acceptability Score

VATS Resection of a 10-Centimeter Mediastinal Mass With Subxiphoid Removal

The Beat With Joel Dunning Ep. 173: Uniportal Robotics in the UAE

Phrenic Nerve Pacing Using a Subxiphoid Robotic Approach Without Lung Isolation

Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid

Effect of Surgical Exposure on Outcomes in BLTx: Insight From the International ECLS Registry

Robotic Radical Thymectomy for Myasthenia Gravis: Left-Sided Approach

The Beat With Joel Dunning Ep. 172: Intraoperative AI Copilot in Robotic Cardiac Surgery

Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: A Brief Report